Bavarian Nordic A/S
CSE:BAVA
Bavarian Nordic A/S
Net Issuance of Common Stock
Bavarian Nordic A/S
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Net Issuance of Common Stock
-kr50.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Net Issuance of Common Stock
-kr78.5m
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Net Issuance of Common Stock
kr6.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
55%
|
CAGR 10-Years
99%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Net Issuance of Common Stock
€315.7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
79%
|
CAGR 10-Years
8%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Net Issuance of Common Stock
kr81.4m
|
CAGR 3-Years
165%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Saniona AB
STO:SANION
|
Net Issuance of Common Stock
kr88.9m
|
CAGR 3-Years
552%
|
CAGR 5-Years
11%
|
CAGR 10-Years
18%
|
|
Bavarian Nordic A/S
Glance View
Bavarian Nordic A/S, established in 1994, is a Danish biotechnology powerhouse distinguishing itself in the development and production of vaccines for infectious diseases and immunotherapies for cancer. The company's journey from a promising start-up to a respected player in the global biotech landscape has been driven by its commitment to innovation and strategic partnerships. Its core operations revolve around a sophisticated platform technology capable of developing vaccines quickly and efficiently. This cutting-edge technology enables Bavarian Nordic to address urgent public health needs, such as growing threats from infectious diseases like smallpox, monkeypox, and Ebola. The company's facility in Kvistgaard is crucial to its operations, allowing it to seamlessly transition from research and development to large-scale production, ensuring a quick response to global health challenges. Revenue generation for Bavarian Nordic is predominantly through contracts and collaborations with governments, health organizations, and pharmaceutical companies. Over the years, the company has secured significant agreements, such as those with the U.S. government for the supply of its smallpox and monkeypox vaccines. These contracts provide a steady income stream, allowing the company to reinvest in its R&D efforts and expand its vaccine pipeline. Moreover, Bavarian Nordic’s strategic acquisitions, like their purchase of Rabipur/RabAvert and Encepur from GlaxoSmithKline, have expanded their portfolio and market presence, providing additional revenue channels. This approach not only sustains the company's growth but also aligns with its long-term vision of addressing unmet medical needs worldwide. By continually leveraging its proprietary technology and expanding its network of strategic collaborations, Bavarian Nordic is well-positioned to advance its mission in the global healthcare arena.
See Also
What is Bavarian Nordic A/S's Net Issuance of Common Stock?
Net Issuance of Common Stock
-50.8m
DKK
Based on the financial report for Mar 31, 2025, Bavarian Nordic A/S's Net Issuance of Common Stock amounts to -50.8m DKK.
You don't have any saved screeners yet